Source: Annual Congress 2007 - Cellular and molecular aspects of pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Hamidi, S. Said (Stony Brook, NY, Northport, NY, United States Of America). Gene expression alterations in mice lacking the VIP gene are conducive to pulmonary arterial hypertension and pulmonary vascular remodeling. Eur Respir J 2007; 30: Suppl. 51, 484

Member's Comments

No comment yet.

Related content which might interest you: Pulmonary arterial hypertension (PAH) in mice lacking the vasoactive intestinal polypeptide (VIP) gene: morphometric evidence for vascular remodeling Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals Year: 2006 Enhancement of pulmonary vascular remodelling and inflammatory genes with VIP gene deletion Source: Eur Respir J 2008; 31: 135-139 Year: 2008 Microarray analysis of pulmonary gene expression in mice lacking the vasoactive intestinal peptide (VIP) gene: confirmation of a role in asthma and pulmonary arterial hypertension (PAH) Source: Annual Congress 2006 - Cellular mechanisms of airway disease Year: 2006 Pulmonary arterial hypertension phenotype in VIP knockout mice Source: Eur Respir J 2006; 28: Suppl. 50, 546s Year: 2006 Loss of Bmp9 does not lead to spontaneous pulmonary hypertension, but attenuates vascular remodeling in experimental models Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension Year: 2020 Towards an understanding of pulmonary arterial hypertension (PAH): gene regulation patterns in pulmonary arterial resistance vessels of patients with PAH Source: Eur Respir J 2006; 28: Suppl. 50, 526s Year: 2006 Interleukin-13-dependent regulation of endothelin-1 expression in pulmonary arterial hypertension Source: Annual Congress 2007 - Pulmonary hypertension Year: 2007 Regulation of connexins by hypoxia in rat pulmonary vascular cells in an in vitro model of pulmonary hypertension Source: International Congress 2017 – Experimental PH Year: 2017 BMPR2 mutation status influences bronchial vascular changes in pulmonary arterial hypertension Source: Eur Respir J 2016; 48: 1668-1681 Year: 2016 In a model of genetic pulmonary hypertension, VIP attenuates pulmonary vascular remodeling and right ventricular hypertrophy Source: Annual Congress 2007 - Pathogenesis and novel therapeutic targets in pulmonary hypertension Year: 2007 CFTR in the regulation of pulmonary vascular tone and remodeling Source: Eur Respir J, 58 (6) 2101861; 10.1183/13993003.01861-2021 Year: 2021 Expression of fetal genes in pulmonary arterial hypertension Source: Annual Congress 2005 - Pulmonary hypertension and fibrosis: novel mechanisms Year: 2005 Endothelial NO and its pathophysiologic regulation Source: Annual Congress 2007 - Role of the endothelium in pulmonary function and disease Year: 2007 Shroom expression is attenuated in hypoxia-induced pulmonary hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 147s Year: 2006 Role of c-Abelson in the loss of genome integrity in endothelial cells in pulmonary arterial hypertension Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension Year: 2020 VEGF reduces pulmonary hypertension and vascular remodeling in pulmonary fibrosis through reduced endothelial apoptosis Source: Annual Congress 2009 - Pulmonary circulation I Year: 2009 TrkB expression is altered in hypoxia-induced pulmonary hypertension Source: Eur Respir J 2007; 30: Suppl. 51, 606s Year: 2007 IL-6 receptor overexpression in pulmonary arterial smooth muscle cells in idiopathic pulmonary hypertension Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease Year: 2015 Spermine promotes pulmonary vascular remodelling and its synthase is a therapeutic target for pulmonary arterial hypertension Source: Eur Respir J, 56 (5) 2000522; 10.1183/13993003.00522-2020 Year: 2020